Overview

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Status:
Completed

Trial end date:
2019-12-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Paliperidone Palmitate
Risperidone